If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Free Content Treating neurocysticercosis medically: a systematic review of randomized, controlled trials

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Download Article:



objective To summarize the evidence from randomized controlled trials on the effects of cysticidal therapy used for treating human cysticercosis.

methods Published and unpublished studies in any language identified through MEDLINE (1966 – June 1999) specialized databases, abstracts, proceedings and contact with experts were analysed. Those which compared, using randomized or quasi-randomized methods, any cysticidal drug with placebo or symptomatic therapy were entered in the study. Data were extracted independently by two reviewers and trial quality assessed. Meta-analysis using fixed effects models calculated provided there was no significant heterogeneity, expressed as relative risk.

results Four trials met the inclusion criteria, treating intraparenchymatous neurocysticercosis with either albendazole or praziquantel compared to placebo or no treatment. In the two trials reporting clinical outcomes, treatment was not associated with a reduction in the risk of seizures, although numbers were small (RR 0.95, 95% CI 0.59–1.51). Four trials reported radiological outcomes, and cysticidal treatment was associated with a lower risk of cyst persistence of scans taken within six months of start of treatment (RR 0.83, 95% CI 0.70–0.99). Subsidiary analysis assuming different outcomes in patients lost to follow-up did not alter the findings of the main analysis.

conclusions There is insufficient evidence to determine whether cysticidal therapy is of any clinical benefit to patients with neurocysticercosis. The review does not exclude the possibility that more patients remain seizure-free when treated with cysticidal drugs. Further testing through placebo-controlled trials is required.

Keywords: cysticercosis; drug therapy; meta-analysis; neurocysticercosis; treatment outcome

Document Type: Research Article

DOI: http://dx.doi.org/10.1046/j.1365-3156.1999.00477.x

Affiliations: 1: Ministry of Health, Santiago, Chile 2: Neurosciences Trials Unit, University of Edinburgh, UK 3: Department of Neurology, All India Institute of Medical Research, New Delhi, India 4: Liverpool School of Tropical Medicine, Liverpool, UK

Publication date: November 1, 1999

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more